AI assistant
Lucid Diagnostics Inc. — Director's Dealing 2025
May 22, 2025
33983_dirs_2025-05-22_93b207f8-68c9-4e14-8cc2-972529985368.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Lucid Diagnostics Inc. (LUCD)
CIK: 0001799011
Period of Report: 2025-05-20
Reporting Person: Matheis Dennis (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2025-05-20 | Common Stock | P | 187098 | $1.2950 | Acquired | 187098 | Direct |
| 2025-05-21 | Common Stock | P | 129684 | $1.3226 | Acquired | 316782 | Direct |
| 2025-05-22 | Common Stock | P | 33218 | $1.3184 | Acquired | 350000 | Direct |
Footnotes
F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.265 to $1.30. inclusive. The reporting person undertakes to provide to Lucid Diagnostics Inc., any security holder of Lucid Diagnostics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1), (2) and (3) to this Form4.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.315 to $1.32, inclusive.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.305 to $1.32, inclusive.